Resistell

Resistell AG is a deep-tech start-up incorporated in 2018 in Basel region.
It is developing the world's fastest Antibiotic Susceptibility Test (AST) based
on analysis of nanoscale vibrations of living cells. The company has transformed
a cutting edge nanomotion technique from EPFL into a technology platform consisting of a hardware, software, algorithmics and big data in the cloud, for wide spectrum of applications in life science.

Resistell is a clinical stage company. The validation of Resistell’s AST is taking place in the University Hospital in Lausanne. The clinical data for first ~100 patients is available and it shows around 98% accuracy with the gold standard. The second multi-site study including 3 European hospitals will start in Q3 2022.

Resistell’s device, Phenotech is CE marked for research market and has CE IVD certification for three bacteria-antibiotic combinations. The company will initiate first sales of R&D devices in Q3-Q4 2022.

Resistell has a very strong cross functional team of 23 employees, BSL2 laboratory for AST testing (to be accredited according to ISO 17025 in Q4 2022/Q1 2023) and own device assembly facility. So far, we produced 23 devices, used in Muttenz  and CHUV and additional 17 are under assembly.

We are currently raising funds in series B for the commercialisation of technology for R&D market and for further development and clinical validation of the diagnostic product. We are searching for CHF 5M to complete our CHF 10M B round.